It seems an understatement to say MAKO Surgical Corp. (NASDAQ:MAKO) has fallen hard from its March 2012 high of nearly $44 per share. To be sure, from MAKO Surgical Corp. (NASDAQ:MAKO)’s current price of around $11.50 per share, the stock would need to nearly quadruple for investors who bought at the peak to recoup their losses:
MAKO Total Return Price data by YCharts.
Been there, done that
The thing is, when you zoom out a bit, you can see that anyone who bought shares of MAKO Surgical Corp. (NASDAQ:MAKO) a mere 18 months earlier is actually sitting on a more than 21% gain — albeit only after enduring one heck of a ride in the meantime:
MAKO Total Return Price data by YCharts.
So what would it take for MAKO Surgical Corp. (NASDAQ:MAKO) to regain its former glory?
Well, for one, remember much of that meteoric rise was the direct result of over-enthusiastic RIO system sales projections, and we all remember what happened when the company failed to live up to those expectations.
In fact, some shareholders were so furious about the ensuing drop that they filed a class action lawsuit, in which they alleged they were misled by management. Of course, I just noted yesterday one such case was dismissed thanks to MAKO Surgical Corp. (NASDAQ:MAKO)’s “forward-looking statements” clauses, but the damage to management’s rapport with investors remains evident even after the company posted two consecutive decent quarters.
Then again, the reason investors were so excited about higher system sales in the first place wasn’t the significant upfront revenue benefit, but rather the resulting long-term increase in the number of procedures. You see, each time a surgery is performed using MAKO Surgical Corp. (NASDAQ:MAKO)’s RIO platform, the company benefits to the tune of roughly $5,000 in recurring revenue from the sale of instruments and implants.
So what’s the problem?
However, surgeons can currently only perform two different types of procedures using MAKO’s system — partial knee replacements and total hip arthroplasty.
Even then, considering that MAKO only just introduced the hip solution in September 2011, only 65% of the 156 systems currently in place are equipped to enable THA. As a result, only 467 of the 2,988 procedures performed last quarter were hip replacements. On a positive note, that did represent an 18.2% sequential increase over the previous quarter, which shows that hospitals are finally beginning to utilize MAKO’s hip replacement tech on a greater sale.
Still, customers who owned MAKO’s RIO robots in 2012 only performed an average of just 6.7 monthly procedures per system last year, and monthly utilization per site fell to 6.6 procedures last quarter. By contrast, consider MAKO’s soft-tissue counterpart in Intuitive Surgical, Inc. (NASDAQ:ISRG), whose customers performed around 13 procedures per month last year with each of Intuitive’s da Vinci robots.
A better way
Of course, while the folks at MAKO can obviously increase the number of total procedures performed by selling new systems, that’s easier said than done given the RIO’s seven-figure price point. Until that growth avenue picks up more steam, then, you can bet MAKO will focus on increasing utilization.
How, then, does Intuitive Surgical, Inc. (NASDAQ:ISRG) manage to maintain such high monthly utilization numbers? Thanks in part to the complementary instrumental requirements of many soft-tissue surgeries, surgeons are able to perform literally dozens of different procedures using Intuitive’s da Vinci platform.
That’s exactly why one of the four big questions I posed going into MAKO’s fourth-quarter report earlier this year revolved around whether the company had news on the development of new surgery types for the RIO. As I noted at the time, CEO Maurice Ferre did tell investors last November the company was working on a total knee replacement solution, but he also warned at the same time we shouldn’t expect to see it in the near future.
